[go: up one dir, main page]

RU99122597A - NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC MEDICINES FOR TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS - Google Patents

NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC MEDICINES FOR TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS

Info

Publication number
RU99122597A
RU99122597A RU99122597/14A RU99122597A RU99122597A RU 99122597 A RU99122597 A RU 99122597A RU 99122597/14 A RU99122597/14 A RU 99122597/14A RU 99122597 A RU99122597 A RU 99122597A RU 99122597 A RU99122597 A RU 99122597A
Authority
RU
Russia
Prior art keywords
mirtazapine
antipsychotic agent
combination according
treatment
prevention
Prior art date
Application number
RU99122597/14A
Other languages
Russian (ru)
Other versions
RU2222330C2 (en
Inventor
Христофорус Луи Эдуард БРУККАМП
Херманус Хенрикус Герардус БЕРЕНДСЕН
Роджер Мартин ПИНДЕР
Original Assignee
Акцо Нобель Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акцо Нобель Н.В. filed Critical Акцо Нобель Н.В.
Publication of RU99122597A publication Critical patent/RU99122597A/en
Application granted granted Critical
Publication of RU2222330C2 publication Critical patent/RU2222330C2/en

Links

Claims (11)

1. Комбинация, содержащая миртазапин и антипсихотическое средство.1. A combination containing mirtazapine and an antipsychotic. 2. Комбинация по п.1, в которой антипсихотическое средство представляет собой типичное или атипичное антипсихотическое средство. 2. The combination according to claim 1, in which the antipsychotic agent is a typical or atypical antipsychotic agent. 3. Комбинация по п.1, в которой антипсихотическое средство выбрано из ацепромазина, хлорпроэтазина, хлорпромазина, циамемазина флуопромазина, метотримепразина, промазина, мезоридазина, перициазина, пиперацетазина, пипотиазина, сульфоридазина, тиоридазина, ацетофеназина, карфеназина, диксиразина, флуфеназина, перазина, перфеназина, прохлорперазина тиопропазата, тиопроперазина, трифлуперазина, хлорпротиксена, флупентиксола, тиотиксена, зуклопентиксола, бенперидола, бромперидола, дроперидола, флуанизона, галоперидола, мелперона, моперона, пипамперона, спиперона, тимиперона, трифлуперидола, флуспирилена, пенфлуридола, пимозида, амисульприда, раклоприда, ремоксиприда, сульпирида, сультоприда, тиаприда, молиндона, оксипертина, клозапина, доксапина, рисперидона, оланзапина, сертиндола, кветиапина в зипразидона. 3. A combination according to claim 1, wherein the antipsychotic agent selected from acepromazine, chlorproethazine, chlorpromazine, tsiamemazina fluopromazina, methotrimeprazine, promazine, mesoridazine, periciazine, piperacetazine, pipotiazine, sulforidazina, thioridazine, acetophenazine, karfenazina, diksirazina, fluphenazine, perazina, perphenazine , prochlorperazine thiopropazate, thioproperazine, trifluperazine, chlorprothixene, flupentixol, thiotixen, zuclopentixol, benperidol, bromperidol, droperidol, fluanisone, haloperidol, melperon, moperon , Pipamperone, spiperone, timiperone, trifluperidol, fluspirilene, penfluridol, pimozide, amisulpride, raclopride, remoxipride, sulpiride, sultopride, tiapride, molindone, oxypertine, clozapine, doksapina, risperidone, olanzapine, sertindole, quetiapine, ziprasidone in. 4. Комбинация по п.1, в которой аптипсихотическое средство выбрано из ацепромазина, хлорпромэтазина, хлорпромазина, циамемазина флуопромазина, метотримепраэина, промазина, мезоридазина, перициазина, пиперацетазина, пипотиазина, сульфоридазина, тиоридазина, ацетофеназина, карфеназина, диксиразина, флуфеназина, перазина, перфеназина, прохлоперазина тиопропазата, тиопроперазина, трифлуперазина, хлорпротиксена, флупентиксола, тиотиксена, зуклопентиксола, бенперидола, бромперидола, дроперидола, флуанизона, галоперидола, мелперона, моперона, пипамперона, спиперона, тимиперона, трифлуперидола, флуспирилена, пенфлуридола, пимозида, амисульприда, раклоприда, ремоксиприда, судьпирида, сультоприда, тиаприда, молиндона, оксипертина, клозапина, локсапина, рисперидона в оланзапина. 4. The combination according to claim 1, in which the aptipsychotic agent is selected from acepromazine, chlorpromethazine, chlorpromazine, cyamemazine fluopromazine, metotrimepraein, promazin, mesoridazine, pericyazin, piperazazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinazinova. , prochloperazine thiopropazate, thioproperazine, trifluperazine, chlorprothixene, flupentixol, thiotixen, zuclopentixol, benperidol, bromperidol, droperidol, fluanisone, haloperidol, melperon, moperon , Pipamperone, spiperone, timiperone, trifluperidol, fluspirilene, penfluridol, pimozide, amisulpride, raclopride, remoxipride, sudpirida, sultopride, tiapride, molindone, oxypertine, clozapine, loxapine, risperidone, olanzapine. 5. Комбинация по любому из пп.1 - 4 для применения в медицинском лечении. 5. The combination according to any one of claims 1 to 4 for use in medical treatment. 6. Фармацевтическая композиция, содержащая комбинацию по любому из пп.1 - 4 в ассоциации с одним или более фармацевтически приемлемыми ее носителями. 6. A pharmaceutical composition comprising a combination according to any one of claims 1 to 4 in association with one or more pharmaceutically acceptable carriers thereof. 7. Способ лечения психотического расстройства у животного, который включает в себя лечение указанного животного терапевтически эффективным количеством комбинации по любому из пп.1 - 4 или комбинации, описанной в п.6. 7. A method of treating a psychotic disorder in an animal, which comprises treating said animal with a therapeutically effective amount of a combination according to any one of claims 1 to 4 or the combination described in claim 6. 8. Применение миртазапина в производстве лекарственного препарата для одновременного или последовательного введения с антипсихотическим средством для лечения и/или профилактики психотического расстройства. 8. The use of mirtazapine in the manufacture of a medicament for simultaneous or sequential administration with an antipsychotic agent for the treatment and / or prevention of psychotic disorder. 9. Применение антипсихотического средства в производстве лекарственного препарата либо для одновременного либо для последовательного введения с миртазапином для лечения и/или профилактики психотического расстройства. 9. The use of an antipsychotic agent in the manufacture of a medicament for either simultaneous or sequential administration with mirtazapine for the treatment and / or prevention of psychotic disorder. 10. Применение миртазапина и антипсихотического средства в производстве лекарственного препарата для лечения и/или профилактики психотического расстройства. 10. The use of mirtazapine and an antipsychotic agent in the manufacture of a medicament for the treatment and / or prevention of psychotic disorder. 11. Упаковка для пациента, содержащая, по меньшей мере, один активный ингредиент, выбранный из миртазапина и антипсихотического средства, и содержащая информационный вкладыш с инструкцией по применению активного ингредиента или активных ингредиентов, в комбинации, содержащей миртазапин и антипсихотическое средство. 11. A package for a patient containing at least one active ingredient selected from mirtazapine and an antipsychotic agent and containing an information leaflet with instructions for using the active ingredient or active ingredients in a combination comprising mirtazapine and an antipsychotic agent.
RU99122597/14A 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents for treatment or prophylaxis of psychotic disorders RU2222330C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97200881.7 1997-03-27
EP97200881 1997-03-27
EP97202785.8 1997-09-11
EP97202785 1997-09-11

Publications (2)

Publication Number Publication Date
RU99122597A true RU99122597A (en) 2001-09-10
RU2222330C2 RU2222330C2 (en) 2004-01-27

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99122597/14A RU2222330C2 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents for treatment or prophylaxis of psychotic disorders

Country Status (24)

Country Link
EP (1) EP0969845B1 (en)
JP (2) JP4377456B2 (en)
KR (1) KR100577865B1 (en)
CN (1) CN1226036C (en)
AR (1) AR012193A1 (en)
AT (1) ATE318604T1 (en)
AU (1) AU726194B2 (en)
BR (1) BR9808077A (en)
CA (1) CA2284551C (en)
CZ (1) CZ298105B6 (en)
DE (1) DE69833645T2 (en)
DK (1) DK0969845T3 (en)
ES (1) ES2259207T3 (en)
HU (1) HUP0002742A3 (en)
ID (1) ID22283A (en)
IL (1) IL123716A (en)
NO (1) NO994673L (en)
NZ (1) NZ337618A (en)
PL (1) PL191449B1 (en)
PT (1) PT969845E (en)
RU (1) RU2222330C2 (en)
TR (1) TR199902334T2 (en)
TW (1) TW587938B (en)
WO (1) WO1998043646A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2232574C2 (en) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН "fluoglysine" medicinal preparation for treating different forms of depression

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (en) * 1999-08-13 2002-10-18 Aventis Pharma Sa USE OF CYAMEMAZINE IN THE TREATMENT OF BENZODIAZEPINES WITHDRAWAL
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
FR2802101B1 (en) * 1999-12-10 2003-02-28 Aventis Pharma Sa COMBINATION OF CYMEMAZINE AND AN ATYPICAL NEUROLEPTIC
MXPA02007095A (en) 2000-01-19 2003-04-14 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine.
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
ES2284830T3 (en) * 2001-02-06 2007-11-16 Astrazeneca Ab USE OF QUETIAPINE FOR THE TREATMENT OF COCAINA.
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1541197B8 (en) * 2003-12-02 2009-06-10 PharmaNeuroBoost N.V. Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
MXPA06014002A (en) 2004-06-03 2007-02-08 Hoffmann La Roche Treatment with cisplatin and an egfr-inhibitor.
US8354121B2 (en) * 2006-06-09 2013-01-15 Dainippon Sumitomo Pharma Co., Ltd. Tape preparation
JOP20120083B1 (en) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
DE102012011839B4 (en) * 2012-06-14 2018-03-22 Norbert Müller Use of interferon-gamma in a method for the treatment of psychiatric disorders
RU2509560C1 (en) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" New therapeutic combinations of mirtazapine applicable in pain conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (en) * 1974-03-07 1975-09-18 Hoechst Ag PHARMACEUTICAL COMBINATION PREPARATIONS WITH PSYCHOTROPIC EFFECT AND METHOD FOR THEIR PRODUCTION
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
NZ241481A (en) * 1991-02-04 1994-06-27 Hoechst Roussel Pharma Derivatives of 8-aza-bicyclo[3.2.1]octane and pharmaceutical compositions thereof
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (en) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Method for treating the cases of endogenous psychoses
KR100333115B1 (en) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 Sustained-release microsphere containing antipsychotic and process for producing the same
JPH07242669A (en) * 1994-03-07 1995-09-19 Akikazu Ogawa Compound bonding tetracyclic system to butyrophenone derivative

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2232574C2 (en) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН "fluoglysine" medicinal preparation for treating different forms of depression

Similar Documents

Publication Publication Date Title
RU99122597A (en) NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC MEDICINES FOR TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
US3625214A (en) Drug-delivery device
AU726194B2 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
US6150353A (en) Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
AU639042B2 (en) Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5472436A (en) Ocular appliance for delivering medication
DE69402343D1 (en) Catheter and needle device for administering therapeutic solutions
SI3061760T1 (en) Derivated derivatives of benzoquinolysin as inhibitors of the vesicular monoamine conveyor 2
KR101901660B1 (en) Bandage for Oral hemostasis and wound protection
KR930701987A (en) Sustained release compositions for treating periodontal disease
ATE177633T1 (en) NON-STEROID ANTI-INFLAMMATORY MEDICINAL AND DECONGESTIRUM EYE MEDICINAL COMPOSITION
FR2753376B1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AMISULPRIDE AND THERAPEUTIC APPLICATIONS THEREOF
AU625402B2 (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
KR20220055901A (en) Wound covering material for oral wound protection and self-treatment using adhesive polymer
Koepke et al. Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis
HK1023293B (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
CA2396351A1 (en) New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
WO2001045688A3 (en) Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients
Smith et al. Drugs of choice for pregnant women
Schiele et al. Tardive dyskinesia: a persistent neurological syndrome associated with antipsychotic drug use
Auvinet et al. A double-blind comparison of piroxicam fast-dissolving dosage form and diclofenac enteric-coated tablets in the treatment of patients with acute musculoskeletal disorders
US20050176782A1 (en) Medicament and method for treating vulodynia
Harrison Standardization of medical records
WOEBER BRITISH 11 December 1965 Correspondence MEDICALJOURNAL 1433
WO2017090902A1 (en) Oral hemostatic and wound-protective film